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Germinal centre protein HGAL promotes lymphoid
hyperplasia and amyloidosis via BCR-mediated Syk
activation
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The human germinal centre-associated lymphoma gene is speciﬁcally expressed in germinal
centre B-lymphocytes and germinal centre-derived B-cell lymphomas, but its function is
largely unknown. Here we demonstrate that human germinal centre-associated lymphoma
directly binds to Syk in B cells, increases its kinase activity on B-cell receptor stimulation and
leads to enhanced activation of Syk downstream effectors. To further investigate these
ﬁndings in vivo, human germinal centre-associated lymphoma transgenic mice were gener-
ated. Starting from 12 months of age these mice developed polyclonal B-cell lymphoid
hyperplasia, hypergammaglobulinemia and systemic reactive amyloid A (AA) amyloidosis,
leading to shortened survival. The lymphoid hyperplasia in the human germinal centre-
associated lymphoma transgenic mice are likely attributable to enhanced B-cell receptor
signalling as shown by increased Syk phosphorylation, ex vivo B-cell proliferation and
increased RhoA activation. Overall, our study shows for the ﬁrst time that the germinal centre
protein human germinal centre-associated lymphoma regulates B-cell receptor signalling in
B-lymphocytes which, without appropriate control, may lead to B-cell lymphoproliferation.
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T
he human germinal centre-associated lymphoma (HGAL)
gene is expressed in germinal centre (GC) B-lymphocytes
and GC-derived B-cell lymphomas1,2. In diffuse large
B-cell lymphoma and classic Hodgkin lymphoma patients, HGAL
expression is associated with improved survival1,3,4. The function
of its murine homologue M17 is unknown; knockout mice
demonstrated reduced-size Peyer’s patches but M17 protein was
dispensable for GC formation and function5. In vitro studies in
human lymphocytes demonstrated that HGAL decreases cell
motility by interacting with F-actin, myosin II and RhoA-speciﬁc
guanine nucleotide exchange factors6–8. HGAL induced RhoA
effects not only on cell migration but also on gene expression7.
These ﬁndings suggest that HGAL may contribute to the control
of GC lymphocyte motility but do not explain the biological
relevance of GC-speciﬁc HGAL expression.
The HGAL protein harbours a modiﬁed immunoreceptor
tyrosine-based activation motif (ITAM) frequently used for B-cell
receptor (BCR) signal transduction. BCR signalling is initiated on
antigen binding to membrane Ig, inducing receptor aggregation
and Src kinase family-mediated tyrosine phosphorylation of
ITAMs in signal-transducing elements Ig-a and Ig-b9. ITAM
phosphorylation creates docking sites for Syk SH2 domains.
Recruitment to the Ig-a/b facilitates Syk phosphorylation, leading
to the activation of signalling molecules that couple the BCR to
multiple downstream signalling pathways. Consequently, Syk has
a key role in BCR signalling and its disruption leads to a block in
B-cell development10–12.
The presence of the ITAM, whose tyrosines can be phos-
phorylated by Lyn2,6, in the HGAL protein, raised a hypothesis
that it might be involved in BCR signalling. We demonstrate that
in vitro HGAL enhances BCR signalling by binding and
increasing Syk activation. To further investigate these ﬁndings
in vivo, HGAL transgenic mice were generated. Although young
mice exhibited normal B-cell development, older HGAL
transgenic animals progressively developed polyclonal lymphoid
hyperplasia and reactive amyloid A (AA) amyloidosis. Overall,
our ﬁndings implicate HGAL in regulating BCR signalling,
suggesting that it may have a role in humoral immune responses.
Results
HGAL enhances intracellular BCR signalling. We analysed
HGAL’s effect on the BCR pathway in response to surface Ig
stimulation (Fig. 1a). In unstimulated lymphoma cells there was
no evidence for Syk, Btk and PLCg2 phosphorylation (not
shown). Following BCR stimulation, Syk, Btk and PLCg2 phos-
phorylation was markedly reduced in lymphoma cell lines on
knockdown of endogenous HGAL by different short interfering
RNA (Fig. 1a and Supplementary Fig. S1a), while Ig-a/b phos-
phorylation was not affected (not shown). Concordantly, ectopic
HGAL expression in lymphoma cells and human peripheral
B-lymphocytes lacking endogenous HGAL protein resulted in
increased Syk phosphorylation (Fig. 1a,b).
In activated B-lymphocytes, Btk, PLCg2 and BLNK constitute
the calcium (Ca2þ ) initiation complex, inducing release of
intracellular Ca2þ and activating protein kinase C, nuclear factor
of activated T cells, nuclear factor kB and mitogen-activated
protein kinase signalling9,13. Consequently, we examined the
effects of HGAL gain and loss of function on the ability of
lymphoma cells to mobilize Ca2þ in response to BCR
stimulation. Following Ig stimulation, HGAL expression in
HBL-1 cells led to increased Ca2þ mobilization (not shown),
while HGAL knockdown in Raji, VAL and BJAB cells markedly
reduced Ca2þ mobilization (Fig. 1c and Supplementary Fig. S1b).
HGAL knockdown in lymphoma cells transfected with constructs
containing either nuclear factor of activated T cells or nuclear
factor kB responsive luciferase reporter genes resulted in
signiﬁcantly decreased reporter activity (Fig. 1d and
Supplementary Fig. S1c). HGAL knockdown in lymphoma cells
also led to decreased extracellular signal-regulated kinase1/2 and
p38 phosphorylation, while Jun N-terminal kinases
phosphorylation was unaffected (Fig. 1e and Supplementary
Fig. S1d), consistent with previous reports14. Overall, these
ﬁndings show that HGAL affects BCR signalling downstream of
the Ig-a/b proteins.
HGAL interacts with Syk and enhances its kinase activity. Syk
has a major role in coupling BCR activation to downstream
effectors. As Syk selectively binds to phosphorylated ITAM10, we
examined for a potential interaction between HGAL and Syk.
Endogenous Syk was detected in immunoprecipitates of
endogenous HGAL from unstimulated Raji and VAL
lymphoma cells (Fig. 2a and not shown). BCR stimulation
increased HGAL and Syk coimmunoprecipitation (coIP)
(Fig. 2a). HGAL protein did not coimmunoprecipitate with
Lyn, Ig-a/b p, Btk, BLNK and PLCg2 in unstimulated and BCR-
stimulated lymphoma cells (not shown). Nanoscope microscopy
of unstimulated Raji cells conﬁrmed HGAL and Syk co-
localization in the cell membrane (Fig. 2b); BCR stimulation
further increased HGAL/Syk co-localization, in concordance with
the coIP ﬁndings. A glutathione S-transferase (GST) pull-down
assay using puriﬁed GST-Syk, GST-Grb2 or GST and TRX-
HGAL proteins demonstrated a direct, speciﬁc interaction. GST-
Syk pulled-down TRX-HGAL; however, non-phosphorylated
HGAL did not bind to GST-Grb2 and GST proteins (Fig. 2c).
To determine whether the Syk tandem SH2 domains mediate
interaction with HGAL protein, we transiently co-transfected
wild-type HGAL with truncated Syk encoding the tandem SH2
domains (amino acids 1–261) into Raji and 293T cells and
repeated the coIP experiments. Truncated Syk protein was
detected in the HGAL immunoprecipitates (Fig. 2d and
Supplementary Fig. S2a), indicating that HGAL protein
interacts with the Syk tandem SH2 domains.
To determine the HGAL interacting domain, HGAL mutants
encoding N-terminal 79 (1–79) or 118 (1–118) aa segments and
tyrosine mutants (Y128F, Y148F and Y106AY107A)
(Supplementary Fig. S2b) were co-transfected with the wild-
type Syk into VAL and 293T cells and coIP experiments were
repeated (Fig. 2e and Supplementary Fig. S2c). Individual
mutations of HGAL tyrosines and HGAL truncations did not
affect Syk binding, suggesting that the ﬁrst 79aa of HGAL were
sufﬁcient to mediate Syk binding.
We next examined whether the HGAL protein stimulates Syk
kinase activity. Syk protein was immunoprecipitated from BCR-
stimulated or unstimulated Raji cells and used in the kinase assay,
either alone or with puriﬁed HGAL protein (Fig. 2f). No Syk
kinase activity was observed in unstimulated cells, even in the
presence of HGAL protein. In stimulated cells, addition of HGAL
protein markedly increased Syk kinase activity, suggesting that
HGAL binding to Syk enhances its kinase activity in BCR-
stimulated cells, underlying the observed increased Syk
autophosphorylation and activation of its downstream effectors.
HGAL gain-of-function mouse model. To examine HGAL
effects on the immune system and BCR signalling in vivo, a Sca1-
HGAL plasmid encoding human HGAL complementary DNA
(cDNA) under the control of the mouse Ly-6E.1 promoter15
(Fig. 3a,b) was used to generate a transgenic mouse model in
which HGAL is expressed in Sca1þ haematopoietic stem (HSC)/
progenitor cells and Sca1þ fraction of mature B cells of C57BL/
6xCBA mice16. A similar approach recapitulated gene functions
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and generated animal models highly similar to human
diseases17–19. Two independent Sca1-HGAL founder lines (102A
and 102B) exhibited normal embryonic and postnatal development
and were used to characterize the transgenic mice phenotype.
A Southern blot comparison of the endogenous M17 and
transgenic human HGAL hybridization signals indicated transgene
copy numbers ranging from 2 to 4 (Fig. 3b). Flow cytometry
studies revealed that only a fraction of B220 splenocytes expressed
Sca1. Similar fractions of B220 splenocytes in young Sca1-HGAL
(4- to 8-week-old) and control mice expressed Sca1 (Supple-
mentary Fig. S3a). While there was a tendency for a smaller Sca1
expressing fraction of B220 splenocytes in older (starting at 12
months of age) Sca1-HGAL mice compared with control animals,
it was not statistically signiﬁcant (Supplementary Fig. S3a).
Immunoﬂuorescence studies using antibody to the V5 tag, fused
to HGAL in the plasmid used to generate the transgenic animal,
detected ectopically expressed human HGAL in both bone marrow
(BM) and spleen cells (Fig. 3c), with no difference in expression
between young and old animals. HGAL expression was not
detected in either mature myeloid, monocyte and T-cell lineages or
in the wild-type controls. Overall, HGAL protein expression levels
were similar to levels observed in the human U2OS cell line
transfected with the same HGAL plasmid used to generate the
transgenic construct (Supplementary Fig. S3b). There was no
difference in the endogenous M17 messenger RNA (mRNA)
expression between Sca1-HGAL and littermate splenocytes
(Supplementary Fig. S3c).
Lymphoid hyperplasia and amyloidosis in Sca1-HGAL mice.
A total of 75 transgenic animals were analysed. Compared with
age-matched controls, 8-week-old Sca1-HGAL animals did not
show any visible changes within the major haematopoietic
compartments (BM, spleen, thymus, peripheral blood and
lymph nodes (LNs)) by ﬂow cytometry and histological exam-
inations (Fig. 4a, Supplementary Fig. S4). Immunization with
sheep red blood cells led to GC formation in both transgenic and
wild-type mice. Flow cytometry analyses did not reveal statisti-
cally signiﬁcant differences in the number of splenic B220þ
PNAþFasþGL7þ GC B cells between the Sca1-HGAL and
control animals (Supplementary Fig. S5a). Immunohistochem-
istry also did not reveal differences in the size and number
of GCs in the spleens of immunized Sca1-HGAL and
control mice (Supplementary Fig. S5b), indicating that young
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Figure 1 | HGAL enhances intracelular BCR signalling. Raji and VAL lymphoma cells were transfected with short interfering RNA (siRNA) for HGAL or
scrambled control siRNA and HBL-1 cells (a) and normal peripheral blood B-lymphocytes (b) transfected with pcDNA3.1-HGAL or pcDNA3.1-mock
plasmids for 48 h. After 1min stimulation with goat F(ab’)2 anti-human IgM, western blot of BCR receptor effectors was performed. HGAL expression and
equal loading were analysed by immunoblotting with HGAL and actin antibodies. (c) Kinetic of calcium mobilization in Raji cells transfected with siRNA for
HGAL or scrambled control siRNA. Arrow indicated the time point of goat F(ab’)2 anti-human IgM stimulation. (d) Raji lymphoma cells were transfected
with ﬁreﬂy luciferase reporter plasmid pNFkB-Luc or pNFAT-Luc and renilla luciferase plasmid pRL-TK and with either siRNA for HGAL or scrambled control
siRNA. Forty-eight hours after transfection, the cells were stimulated for 10min with goat F(ab’)2 anti-human IgM and luciferase activities were detected
with the dual luciferase assay kit. Numbers refer to luciferase activities representing three independent experiments, each performed in triplicate. * Indicate
statistically signiﬁcant difference (NFkB P¼0.0001 and nuclear factor of activated T cells P¼0.001 by two-tailed Student’s t-test). Data are presented as
mean±s.d. of the mean. (e) BJAB lymphoma cells were transfected with siRNA for HGAL or scrambled control siRNA for 48 h. After stimulation with goat
F(ab’)2 anti-human IgM, cell lysates were used for western blot of mitogen-activated protein kinase/extracellular signal-regulated kinase pathway effectors
at indicated time points. HGAL knockdown or expression and equal loading were conﬁrmed by immunoblotting with HGAL and actin antibodies.
Normalized densitometry measurements are shown below the corresponding blots. Results in (a–e) are representative of three independent experiments.
NFkB, nuclear factor kB.
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Sca1-HGAL mice respond normally to T-cell-dependent antigen
stimulation.
Starting at 12 months of age, the Sca1-HGAL mice demon-
strated increased-sized Peyer’s patches compared with control
animals (Fig. 3d) and expressed HGAL protein at levels similar to
ones observed in human Payer’s patches. These animals also
exhibited non-statistically signiﬁcant decrease in number of BM
immature and pro- and pre-B-cells at the expense of recirculating
B cells (B220þ IgDhi) (Fig. 4a,b). All the Sca1-HGAL mice
became ill, showing decreased spontaneous movements in the
cage, increased respiratory rates, piloerection and shivering, and
died between 12 and 22 months, exhibiting statistically signiﬁcant
shorter overall survival (Fig. 5a).
Macroscopic analysis of these animals revealed massive spleno-
megaly (Fig. 5b). The overall microscopic architecture of the spleen
was preserved; however, the splenic sinusoids were dilated and
distorted by large quantities of proteinaceous deposits, which were
also present surrounding small and medium-calibre splenic blood
vessels (Fig. 5c). These deposits were found adjacent to expanded
white-pulp areas showing lymphoid hyperplasia with preserved
periarteriolar lymphoid sheaths. Immunohistochemistry using B220
and PAX5 antibodies highlighted a signiﬁcant proportion of the
expanded white pulp representing B cells, whereas CD3 highlighted
a slightly smaller proportion of T cells. B220 staining was weak
compared with that of PAX5, although both stains showed an
equivalent distribution of B cells. Staining for IRF4 highlighted
T-cell areas in addition to a few scattered plasmacytoid cells.
PNAbio showed no signiﬁcant staining within the white-pulp,
suggesting that white-pulp expansions represented lymphoid
hyperplasia without GC formation (Fig. 5c). Control animals
showed a similar distribution of B and T cells within the white-
pulp, although without lymphoid hyperplasia (Supplementary
Fig. S6a). In both Sca1-HGAL and control animals, CD38 (not
shown) and CD138 showed weak expression in the B cells without
the intense expression typically seen in plasma cells (Fig. 5c and
Supplementary Fig. S6a). Flow cytometry also did not demonstrate
differences in the number and percentage of B220loCD138þ
splenic cells between young and old Sca1-HGAL and control mice
(Supplementary Fig. S6b). In contrast, ﬂow cytometry analysis
detected IgMþ B-cells in peripheral blood and BM (Fig. 5d,e),
conﬁrming that the observed splenic lymphoid hyperplasia was due
to follicular (FO) B cells (Fig. 5f). The percentage of Sca1þLin
cells in BM did not increase in Sca1-HGAL mice compared with
normal littermates (data not shown). Analysis of the B-1 lympho-
cyte population in the older animals revealed a signiﬁcant decrease
in B-1 cell number and percentage in the spleen and a signiﬁcant
increase in the LN of the Sca1-HGAL mice compared with normal
littermates (Supplementary Fig. S4). There was no difference in the
number and percentage of B-1 and B-1a cells in the BM and
peritoneum between the Sca1-HGAL and control animals.
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western blot, respectively. (b) Unstimulated or stimulated Raji cells (as described in a) were stained with HGAL (green) and Syk (red) antibodies. Scale bar,
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Congo red and trichrome stains of the spleens for amyloid
showed distinctive positive staining of the proteinaceous deposits;
Congo red showed the characteristic muted orange colour on light
microscopy and exhibited apple-green birefringence under polar-
ized light. Similarly, the trichrome stain showed a greyish-blue
colour, consistent with amyloid deposition and in contrast to the
bright turquoise blue that is typically demonstrated by collagen
(Fig. 5c). Tissue sections from multiple organs including the kidney,
liver, lung and small intestine showed similar massive amyloid
deposition (Supplementary Fig. S7a,b). Sections of the kidney, liver
and lung showed preservation of the normal architecture with
modest mixed lymphoid inﬁltrates that were absent in control
animals. Massive amyloid deposition was observed in all renal
glomeruli, as well as the interstitium. Amyloid deposition was also
seen surrounding small and medium calibre blood vessels in the
kidneys, lung and liver, but not the heart. Electron microscopy of
spleen specimens conﬁrmed the presence of amyloid deposits
(Supplementary Fig. S7c,d). Liquid chromatography tandem mass
spectrometry analysis of the kidney and spleen specimens showed
that the most abundant pathogenic protein in the amyloid deposits
was serum amyloid-associated protein-2, consistent with AA
amyloidosis (Fig. 6). Analysis of serum amyloid-associated protein-
2 peptide sequences revealed the absence of 33 aa of the C terminus,
suggesting these residues were cleaved during the amyloidogenesis,
similar to what has been described in human AA amyloidosis20.
Like in human amyloidosis, constituents of many human amyloid
types (apolipoprotein E, apolipoprotein A-IV, serum amyloid
P-component and apolipoprotein A-I) were also detected in the
amyloid deposits in the Sca1-HGAL mice.
To examine whether the observed lymphoid hyperplasia were of
clonal origin, DNA extracted from the splenic B-lymphocytes from
Sca1-HGAL mice were subjected to Southern blot using the 30 JH4
probe. No Ig heavy chain (IgH) gene rearrangements were
detected (Supplementary Fig. S8a). Polymerase chain reactions
followed by direct sequencing or cloning and sequencing of multiple
molecular clones also failed to detect predominant monoclonal
products (Supplementary Fig. S8b), further indicating that the
observed lymphoid hyperplasia were of polyclonal origin.
Cytogenetic and ﬂuorescence in situ hybridization studies of the
splenic B-lymphocytes from lymphoid hyperplasia demonstrated
normal karyotypes without evidence for Bcl2-IgH translocation
(not shown).
Sca1-HGAL mice display hypergammaglobulinemia. The
presence of polyclonal FO B-cell lymphoid hyperplasia in the
Sca1-HGAL transgenic mice pointed to possible immune stimu-
lation, potentially leading to hypergammaglobulinemia. The
non-immunized Sca1-HGAL mice produced antibodies of all
isotypes and IgG titres tended to be higher than in the wild-type
controls, reaching statistical difference for IgG1 isotype (Fig. 7a).
Enhanced BCR signalling in lymphoid hyperplasia splenocytes.
The observed lymphoid hyperplasia in the Sca1-HGAL mice
might be attributed to increased B-cell proliferation due to
enhanced BCR signalling or to promotion of B-cell survival. To
differentiate between these mechanisms, we examined ex vivo
B-cell proliferation in response to BCR stimulation (Fig. 7b).
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There was no difference in cell proliferation rates between control
and young Sca1-HGAL mouse groups at all analysed IgM con-
centrations. In contrast, B-cells from Sca1-HGAL mice with
lymphoid hyperplasia demonstrated increased proliferation to 0.5
and 2 mgml 1 anti-IgM antibody concentrations compared with
both wild-type controls and young transgenic mice. However,
B-cell proliferation was similar in all the three types of animals at
saturating 8 mgml 1 anti-IgM antibody concentrations. Splenic
B-cell surface Ig expression was similar in all the three types of
analysed animals (not shown). These ﬁndings suggest that
B-lymphocytes from Sca1-HGAL mice with lymphoid hyperpla-
sia show enhanced sensitivity to surface Ig stimulation. Con-
cordantly, increased Ca2þ mobilization (Fig. 7c) and Syk
phosphorylation (Fig. 7d) were observed in the BCR-stimulated
B-cells from Sca1-HGAL mice with lymphoid hyperplasia com-
pared with control animals. In contrast, isolated B220þ sple-
nocytes from Sca1-HGAL transgenic and control mice
supplemented only with 5% FCS exhibited a similar in vitro
overtime death rate (Supplementary Fig. S9), suggesting that
HGAL does not promote B-cell survival in the Sca1-HGAL mice.
RhoA activation in Sca1-HGAL transgenic mice. Our previous
in vitro studies demonstrated that HGAL induces RhoA activa-
tion in human B-cells7. Consequently, we examined the levels of
GTP-bound RhoA in B-cell splenocytes isolated from Sca1-
HGAL transgenic mice with and without lymphoid hyperplasia.
RhoA-GTP levels were signiﬁcantly higher in Sca1-HGAL B-cells
from spleens with versus without lymphoid hyperplasia
(P¼ 0.006, analysed by two-tailed Student’s t-test) (Fig. 7e),
corroborating the observed activation of this pathway in human
B cells.
Transcriptome changes in Sca1-HGAL transgenic mice. To
comprehensively assess the global effect of HGAL on lymphocyte
functions and the observed lymphoproliferation, we performed
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Figure 4 | Analysis of the BM and spleen cell lineages in the Sca1-HGAL mice. Cells from the BM and spleen of young (8 weeks) and old (more than
7-month-old) age-matched Sca1-HGAL mice and wild-type controls (n¼ 11 in each group) were analysed by ﬂow cytometry. (a) Total cell number of the
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(b) Representative FACS plots of 12-month-old Sca1-HGAL mice are displayed. FACS deﬁnition of B-cell developmental stages was performed according to
Kwon et al.37
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gene expression proﬁling using isolated CD22þB220þ spleno-
cytes from adult Sca1-HGAL mice with hyperplastic follicles and
wild-type littermates (four samples each).
In supervised analyses using signiﬁcance analysis of micro-
arrays21 at a 10% false discovery rate (FDR), we identiﬁed 981
genes with signiﬁcantly increased expression in B-splenocytes
from adult Sca1-HGAL mice with lymphoid hyperplasia
compared with controls (Supplementary Data 1). Fig. 8a depicts
107 of these genes (Supplementary Data 2), focusing on those
with at least threefold change between the specimens from Sca1-
HGAL transgenic and control mice. In concordance with HGAL’s
role in regulating lymphocyte motility, gene expression proﬁles in
the Sca1-HGAL mice with lymphoid hyperplasia apparently
reﬂect ‘Cell Movement’ (P¼ 5.46e-9, IPA) and ‘Migration of
Cells’ (P¼ 0.0001, IPA) as evidenced by signiﬁcant overlap with
the corresponding pathways using the Ingenuity Pathway
Analysis knowledge base. Sca1-HGAL B-splenocytes also
exhibited decreased mRNA expression of regulator of G-protein
signalling 13 and 18 (RGS13 and RGS18), whose downregulation
may enhance the signalling activity of G-proteins potentially
enhancing RhoA activation.
We also observed signiﬁcant induction of BCR pathway
components in the Sca1-HGAL mice (Fig. 8a,b), including Ig
heavy chain genes (Ighg1, Igh-2 (IgA), Ighg2b, Ighg2c), corrobo-
rating our observation of serum hypergammaglobulinemia
(Fig. 7a). Within these lymphoid hyperplasias we also observed
signiﬁcant induction of CD80 (Fig. 8b), which costimulates
T-lymphocytes, a ﬁnding which we conﬁrmed at the protein level
(Fig. 8c), demonstrating CD80 expression in a fraction of
B-lymphocytes. No signiﬁcant differences in expression levels of
mRNAs for CD86 (B7-2), CD69, CD5 or MHC-II antigens were
detected.
To evaluate the relative representation of normal
differentiation states within splenocytes from Sca1-HGAL mice
with hyperplastic follicles compared with B cells from wild-type
littermates, we utilized gene set enrichment analysis (GSEA) of
transcriptional proﬁling data. Classiﬁcation signatures from
normal murine stages of B-cell differentiation were obtained
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from Green et al.22 to assess expression bias in Sca1-HGAL
compared with control B cells. Gene expression signature
corresponding to both the normal FO/marginal zone (FO/MZ)
and the plasma cell B-cell differentiation states were signiﬁcantly
enriched in Sca1-HGAL B-cells (Fig. 8d,e). Conversely, signatures
corresponding to the remaining differentiation states were
signiﬁcantly enriched in control B cells, suggesting a relative
over-representation of B cells at the FO/MZ and plasma cell
differentiation states in Sca1-HGAL mice with hyperplastic
follicles. To further validate the role of HGAL in these B-cell
differentiation states, we performed a reciprocal analysis of Sca1-
HGAL signatures in transcriptional proﬁling data from normal
murine B cells22. Genes found to be highly expressed in Sca1-
HGAL B cells compared with control B cells (Fig. 8a) were tested
for enrichment in normal FO/MZ and plasma B cells and
compared with B cells of other differentiation states. This revealed
a signiﬁcant enrichment of HGAL-induced genes in normal FO/
MZ B cells, but not in normal plasma cells, compared with other
differentiation states (Supplementary Fig. S10a–c). The lack of
signiﬁcant enrichment in normal plasma cells is likely the result
of downregulation of a subset of HGAL-induced genes within this
differentiation state. Together, these results suggest that Sca1-
HGAL B cells possess transcriptional signatures indicative of an
over-representation of FO/MZ B cells and plasma cells. However,
immunohistochemistry and ﬂow cytometry studies did not show
an increase in plasma cells in the lymphoid hyperplasia observed
in the Sca1-HGAL mice, suggesting that the B220þ cells may be
poised towards plasma cell differentiation; however, induced
transcriptional changes characteristic to plasma cells were
insufﬁcient to lead to plasma cell differentiation. Indeed, the
observed transcriptional signatures lacked expression of PRDM1
and XBP1, genes necessary for plasma cell genesis. Furthermore,
normal murine FO/MZ B cells had signiﬁcantly enriched
expression of HGAL-induced genes, suggesting that HGAL may
have a role in normal FO/MZ B-cell biology.
We also compared the transcriptional responses evoked by
HGAL in B-cell lymphoid hyperplasia of Sca1-HGAL mice to those
induced in other B-cell tumours at various stages of the B-cell
lineage, with a focus on those arrested at the GC and beyond23,24.
Notably, genes induced in the lymphoid hyperplasia in the Sca1-
HGAL mice signiﬁcantly overlapped those upregulated in murine
GC-derived lymphomas driven by Bcl6 (ref. 24) (P¼ 2.48e 4 by
hypergeometric test) (Supplementary Fig. S10d) and were also
enriched for those uniformly repressed within plasma cell tumours
driven by Myc/Bcl-xL23 (P¼ 1.8e 12 by hypergeometric test)
(Supplementary Fig. S10e), suggesting a distinct regulatory
programme in these hyperplasia leading to Ig secretion.
Discussion
The outcome of BCR stimulation is diverse and is determined by
the maturation state of the cell, the nature and quantity of the
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Figure 6 | Analysis of amyloid ﬁbrils. (a) Congo red-stained kidney specimen viewed under ﬂuorescent light source with bright red areas representing
amyloid deposits. Purple coloured lines-areas microdissected for MS-based proteomic analysis. (b) Results of MS-based proteomic analysis of amyloid
plaques from the kidney and spleen specimens in two independent microdissections. The identiﬁed proteins are listed according to their relative abundance,
with top 25 from a total of 720 proteins shown. The columns show the protein name, the UnitProt identiﬁer (protein accession number in the UniProt
database, http://www.uniprot.org/), the molecular weight of the protein, two microdissections of the kidney specimen and two microdissections of the
spleen specimen. The numbers indicate number of total peptide spectra identiﬁed for each protein. The amyloid-associated proteins are identiﬁed by yellow
stars. The peptides representing the serum amyloid A-2 protein (red box) are the primary cause of amyloid deposits in the Sca1-HGAL mouse model.
(c) serum amyloid-associated protein-2 (SAA2) protein coverage in the Sca1-HGAL mouse amyloidosis model. The amino-acid (aa) sequence of the
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spectrometry. The ﬁrst 19 aa represent the N terminus signal peptide of the SAA2_MOUSE (red box) cleaved before the mature SAA2_MOUSE is secreted
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antigen, signals from coreceptors and the magnitude and
duration of BCR signalling. An ‘on-off’ mode of BCR signal
transduction would not allow for diverse cellular responses. Fine-
tuning the magnitude and duration of BCR signalling and
preferential activation of speciﬁc downstream signalling compo-
nents by adaptor proteins selectively expressed during B-cell
development is of paramount importance for B-cell functional
plasticity25,26. We demonstrate that the GC-speciﬁc adaptor
HGAL regulates BCR signalling by direct binding and activation
of Syk. While HGAL is not necessary for GC formation5, HGAL
transgenic animals exhibited increased-size Peyer’s patches, a
ﬁnding corroborating the reduced-size Peyer’s patches in the M17
knockout mice5. This observation suggests a speciﬁc function of
HGAL in Peyer’s patches. Furthermore, it is possible that the
increased-size HGAL expressing Peyer‘s patches may contribute
to systemic lymphoid hyperplasia and subsequent development of
AA amyloidosis, which was never observed in the absence of
lymphoid hyperplasia. HGAL-mediated enhancement of BCR
signalling may be important for efﬁcient and timely completion
of the GC reaction and selective activation of signalling pathways
(for example, extracellular signal-regulated kinase and p38 but
not Jun N-terminal kinases). Based on the presented mouse
model, HGAL expression predisposes to lymphoid hyperplasia,
polyclonal hypergammaglobulinemia and enhanced proliferation
in response to BCR stimulation, culminating in systemic AA
amyloidosis. B-lymphocytes in HGAL transgenic mice showed
enhanced activation of Syk and RhoA signalling, suggesting this
model recapitulates the biological effects of HGAL protein in
human B cells. The observed polyclonal lymphoid hyperplasia
was characterized by an accumulation of FO lymphocytes in the
absence of GC lymphocytes and terminally differentiated plasma
cells. The FO B cells in the lymphoid hyperplasia exhibited
transcriptional signatures characteristic to FO/MZ B cells and
plasma cells and were accompanied by polyclonal hyper-
gammaglobulinemia in the absence of mature plasma cells,
suggesting a block in terminal plasma cell differentiation whose
nature is currently unknown. Studies examining HGAL’s effects
on transcriptional signatures in human B cells are ongoing. In
addition, whether the observed phenotype was due to expression
of HGAL in the transgenic lines starting from progenitor and not
speciﬁcally in the GC cells will need to be addressed.
B-cell activation in the Sca1-HGAL mice led to reactive
systemic AA amyloidosis not observed in the control animals.
The molecular features and anatomical location of the observed
amyloid deposits precisely recapitulated human AA amyloidosis
complicating chronic inﬂammatory diseases (for example,
rheumatoid arthritis). In these diseases reactive FO hyperplasia
and lymphadenopathy are commonly observed27 and frequently
precede development of systemic amyloidosis. Heretofore,
temporary AA amyloid deposits were induced in mice by
exogenous agents (for example, casein, lipopolysaccharide), that
would resolve without continued stimulation. Progressive and
permanent AA amyloid deposits were observed in interleukin-6
and serum amyloid A activating factor 1 transgenic mice starting
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form 3–14 months of age28,29. In these models interleukin-6 and
serum amyloid A activating factor directly stimulated serum
amyloid A production, bypassing the preceding chronic
inﬂammatory state observed in human disease. Conversely,
HGAL mice develop AA amyloid deposits in a similar
timeframe and show systemic lymphoid hyperplasia and
hypergammaglobulinemia preceding amyloidosis onset,
therefore, authentically recapitulating human amyloidosis
associated with chronic inﬂammatory disorders. These mice
may thus serve as an excellent model for this disease.
The polyclonal lymphoid hyperplasia observed in the Sca1-
HGAL mice were similar to the lymphoid hyperplasia detected in
the BCL2 transgenic mice models, which also displayed
polyclonal hypergammaglobulinemia. However, the mechanisms
underlying these phenomena were different (increased cell
proliferation and decreased apoptosis, respectively)30.
Additional differences between these models are also noticeable.
BCL2 transgenic mice develop lymphoid hyperplasia earlier than
Sca1-HGAL mice, display autoimmune complex glomeru-
lonephritis and a proportion of these animals develop
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lymphomas that were not detected in the Sca1-HGAL mice30–33.
In contrast, inﬁltration of normal organs by B-lymphocytes and
amyloidosis was observed only in the Sca1-HGAL mice.
HGAL is expressed in the GC-derived B-cell lymphomas, but
whether it has a role in lymphomagenesis is unknown. The Sca1-
HGAL mice developed lymphoid hyperplasia, but not lympho-
mas. However, it is possible that HGAL may facilitate the
transformation process. Gene expression arrays demonstrated
signiﬁcant overlap between genes upregulated in the lymphoid
hyperplasia of the Sca1-HGAL mice and lymphomas driven by
Bcl6/lMyc24. It is possible that the BCR-mediated proliferation
detected in the Sca1-HGAL mice may cooperate with the
antiapoptotic effects induced by BCL2 or differentiation arrest
induced by BCL6 during the transformation process. Previous
studies demonstrated similar cooperation between BCR and Myc
in the genesis of B-cell lymphomas34. Use of the Sca1-HGAL
mouse model to generate bitransgenic mice will help to elucidate
the potential role of HGAL in lymphomagenesis.
Methods
Mice and cell culture. Human non-Hodgkin lymphoma cell lines Raji, VAL, BJAB
and HBL-1 were grown as previously reported35. Human B-lymphocytes were
isolated from healthy donor blood using EasySep Human B cell enrichment kit
(StemCell Technologies, Vancouver, BC, Canada).
A Sca1-HGAL plasmid in which HGAL cDNA is under the control of the mouse
Ly-6E.1 promoter was generated as follows: the fragment containing the human
HGAL-V5 cDNA, was inserted into the ClaI site of the pLy6 vector15, resulting in
Sca1-HGAL vector. The transgene fragment (Fig. 3a) was excised from the vector
by restriction digestion with NotI, puriﬁed for injection (2 ng ml 1) and injected
into CBAxC57BL/6J fertilized eggs. Transgenic mice were identiﬁed by Southern
analysis of tail snip DNA after EcoRI digestion. HGAL cDNA was used as a probe
for detection of the transgene. The transgene copy number was determined by
Southern blot analysis using copy standards prepared by mixing non-transgenic tail
DNA with a known amount of transgene DNA as described in Camper36.
A total of 47 and 28 animals derived from founder lines 102A and 102B,
respectively, housed in pathogen-free conditions were used for the analyses. There
were no differences between the founder lines. All animal experiments were
performed in accordance with the guidelines of the Committees on Animal
Research at University of Salamanca and University of Miami, and the National
research Council.
For cell sorter separation, B220 and CD22 lineage markers were used to purify
cells from the spleen of both Sca1-HGAL or control wild-type mice by
ﬂuorescence-activated cell sorting (FACS) (FACSVANTAGE; Becton Dickinson).
Purity of the sorted cells was over 98%, as determined by FACS reanalysis.
Alternatively, mouse B-lymphocytes were isolated from mice spleen using EasySep
mouse B-cell enrichment kit (StemCell Technologies).
For analysis of B1 and B2 lymphocyte populations, single-cell suspensions were
obtained from the spleens, LN, BM and peritoneal cavities of individual Sca1-
HGAL and control mice. To obtain peritoneal cells, 6ml of ice-cold PBS 1% fetal
calf serum (FCS) were injected into the peritoneal cavity using a 25-g needle
attached to a syringe. After injection, the peritoneum was gently massaged and cells
were collected using a 5-ml syringe. Cells were washed with PBS 1% FCS and
incubated for at least 5min with CD16/CD32 Fc Block (clone 2.4G2) to minimize
background staining. A total of 2 106 cells were stained for 30min on ice with
IgD-FITC (clone 11-26c.2a), CD5-PE (clone 53–7.3), Mac1-PerCP-Cy5.5 (clone
M1/70) and IgM-APC (II/41) to identify the B2 and B1 cell subsets. All the
antibodies were purchased from the BD Pharmingen. At least 1 105 cells were
acquired using a BD C6 Accuri (BD Biosciences) and analysed by the Flowjo
software (Tree Star).
Antibodies, plasmids and chemicals, as well as procedures for cell tranfection,
western blotting, immunoprecipitation, RhoA activity, GST pull-down and
luciferase reporter assays are described in the Supplementary Methods.
Flow cytometry and immunoﬂuorescence microscopy. Nucleated cells were
obtained from total BM (ﬂushing from the long bones), peripheral blood, thymus,
LN and spleen. Contaminating red blood cells were lysed with RCLB lysis buffer
and the remaining cells were then washed in PBS with 1% FCS. After staining, all
cells were washed once in PBS with 1% FCS containing 2mgml 1 propidium
iodide (PI) to allow dead cells to be excluded from both analyses and sorting
procedures. The samples and the data were analysed in a FACSCalibur using
CellQuest (Becton Dickinson) or FlowJo (Tree Star) software. Speciﬁc ﬂuorescence
of FITC, PE, PI and allophycocyanin excited at 488 nm (0.4W) and 633 nm
(30mW), respectively, as well as known forward and orthogonal light scattering
properties of mouse cells were used to establish gates. For each analysis a total of at
least 50,000 viable (PI ) cells were assessed.
FACS deﬁnition of B-cell developmental stages was performed according to
Kwon et al.37 with minor modiﬁcations: BM pro-B cells (CD19þ c-Kitþ ), BM pre-
B cells (B220þCD25þ IgM–), BM immature B-cells (B220þ IgMhiIgD ), BM
recirculating B-cells (B220þ IgDhi), peripheral transitional B-cells
(B220þ IgMhiIgDhi), peripheral mature-B cells (B220þ IgMloIgDhi), MZ B cells
(B220þCD21hiCD23lo), FO B cells (B220þCD21intCD23hi).
The subcellular localization of HGAL and Syk was assessed by stimulated
emission depletion ﬂuorescence nanoscope images38, as described in detail in the
Supplementary Methods, together with the methodology for the immunohisto-
chemistry and analysis of amyloid ﬁbril protein.
Gene expression analysis. Using ﬂow cytometry, CD22þB220þ splenocytes
from adult Sca1-HGAL mice with hyperplastic follicles and wild-type littermates
(four samples each) were sorted to B98% purity, and proﬁled the corresponding
gene expression patterns using Affymetrix GeneChip Mouse Gene 1.0 ST Arrays.
Raw array microarray data ﬁles were submitted to GEO and are available under the
accession number GSE35400. For probeset summarization, microarray CEL data
ﬁles were subjected to a custom Chip Deﬁnition File (MoGene10stv1_Mm_EN-
TREZG_13.0.0) with a mapping of probes to Entrez Gene Identiﬁers as previously
described39. Gene level data were normalized using robust multichip average
within the BioConductor environment40. Signiﬁcance analysis of microarrays21 at a
10% FDR was used to identify the probe sets with signiﬁcant differential expression
between experimental conditions. We used DAVID41, Ingenuity Pathway Analysis
tools (IPA 9/2011 Release), and the Molecular Signatures Database (MSigDB,
v3.0)42, to assess whether differentially expressed genes show functional
enrichment.
For assessment of differentiation state, normal murine B-cell differentiation state
signatures corresponding to Pro-B/Pre-B, transitional, FO/MZ, GC, plasmablast
and plasma cell stages of differentiation were used as previously deﬁned22. Over-
representation of differentiation states within Sca1-HGAL compared with control
B cells was inferred by assessing comparative enrichment of normal differentiation
state signatures using GSEA42. GSEA was performed using a weighted enrichment
statistic, signal-to-noise ratio ranking metric, and corrected for multiple hypothesis
testing using 10,000 permutations to provide a multiple hypothesis testing-
corrected FDR q-value. Reciprocal analysis was performed in order to validate
positive enrichments within Sca1-HGAL B cells. Therein, publicly available gene
expression data of normal murine B-cell differentiation states (GSE26408) was used
to probe for enrichment of HGAL-induced genes within the FO/MZ and plasma
cell differentiation states compared with all other differentiation states (1-versus-all
analysis) using GSEA.
Figure 8 | Transcriptional signatures evoked in vivo within B-cell lymphoid hyperplasia in the Sca1-HGAL mice. (a) Genes signiﬁcantly induced or
repressed within puriﬁed B220þ splenocytes of Sca1-HGAL mice in comparison with wild-type littermates, as determined by signiﬁcance analysis of
microarrays using an FDR 10% and demonstrating at least threefold change. Each row represents a separate gene and each column a separate mRNA
sample from each of eight mice, with four mice from within each group. The level of expression of each gene in each sample, relative to the mean level of
expression of that gene across all the samples, is represented using a red–green colour scale, extending from ﬂuorescence ratios of 0.25 to 4 ( 2 to þ 2 in
log base 2 units). Selected genes are highlighted. (b) Depicted are the relative mRNA expression levels for selected genes exhibiting signiﬁcant differential
expression from a, including Igh-2 (IgA), Ighg1 (IgG1), Ighg2b (IgG2b) and Cd80 (CD80). These genes were independently assessed for differential
expression of the corresponding proteins (in parentheses), as depicted in Fig. 7a, and panel c. (c) Induction of CD80 cell surface protein expression in B-cell
splenocytes of the Sca1-HGAL mice measured by ﬂow cytometry. Data are representative of three mice. (d) GSEA of the relative representation of
differentiation states within Sca1-HGAL compared with control B-cells. Gene expression data from Sca1-HGAL B cells showed signiﬁcant enrichment for
signatures corresponding to both FO/MZ and plasma cell normal murine B-cell differentiation states, suggesting an over-representation of these states
within Sca1-HGAL cells. Signatures corresponding to other differentiation states were signiﬁcantly enriched in control B cells, suggesting a relative under-
representation in Sca1-HGAL B cells. (e) Detailed view of GSEA results, showing a strong bias of genes from normal FO/MZ B cells (left panel) and plasma
cells (right panel) in Sca1-HGAL B cells compared with control B cells.
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Statistical analysis. To test the differences in responses between cells, we used the
two-way analysis of variance test for ex vivo B-cell proliferation assay and two-
tailed Student’s t-test for remaining experiments. Mice survival curves were esti-
mated using the product-limit method of Kaplan–Meier and were compared using
the log-rank test. P-values o0.05 were considered statistically signiﬁcant.
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